Lexotan(Lexotanil)
Bromazepamum
Lexotan and Lexotanil are different trade names for the same drug.
Lexotan contains bromazepam, which is an anxiolytic drug belonging to the benzodiazepine group.
Lexotan is indicated for the treatment of anxiety disorders, including generalized anxiety disorders, autonomic dysfunction, and anxiety states associated with chronic organic brain diseases.
The patient should be under the doctor's supervision throughout the treatment period - at the beginning of treatment to determine the minimum effective dose and the frequency of administration, and during treatment to prevent overdose.
Amnesia
Benzodiazepines can cause anterograde amnesia. This condition occurs most often a few hours after taking the medicine. To reduce the risk of anterograde amnesia, the patient should have uninterrupted sleep for several hours. The effect of anterograde amnesia may be associated with abnormal behavior.
Psychological reactions
When taking benzodiazepines, reactions such as anxiety, agitation, irritability, aggression, anxiety, delusions about the external environment or one's own condition, outbursts of anger, nightmares, hallucinations, psychosis, abnormal behavior, and other undesirable behaviors may occur. If such symptoms occur, the doctor should be contacted immediately.
These symptoms may occur with greater probability in children and the elderly.
Duration of treatment
The duration of treatment is limited (not exceeding 8-12 weeks), and the dose of the medicine should be gradually reduced under the doctor's supervision. During the withdrawal of the medicine, a rebound phenomenon may occur (see section 3, "Discontinuation of Lexotan").
Consumption of alcohol or use of drugs that depress the activity of the central nervous system
During the use of Lexotan, the patient should not drink alcohol or take drugs that depress the activity of the central nervous system.
Alcohol may enhance the effect of Lexotan and cause severe sedation symptoms, as well as respiratory or circulatory depression, which can lead to coma or death.
Tolerance
In the case of repeated use of Lexotan for a longer period, the effectiveness of the medicine may decrease.
During treatment with benzodiazepines, if the used medicine is replaced with a benzodiazepine with a significantly shorter half-life, withdrawal symptoms may develop.
Benzodiazepines should not be used as the only medication in the treatment of depression or anxiety states associated with depression (in the case of these diseases, there may be a greater tendency to commit suicide).
Benzodiazepines should not be used as the first-line treatment for psychotic disorders.
During the use of the medicine, due to its muscle relaxant effect, there is a risk of falls and hip fractures, especially in older patients when getting up at night.
Past abuse of alcohol, drugs, or narcoticsThe medicine should be used with special caution, strictly according to the doctor's instructions.
Dependence on the medicine
Taking benzodiazepine medicines, including Lexotan, or similarly acting medicines, can lead to the development of physical and psychological dependence on these medicines. The risk of dependence increases with the dose and duration of treatment. The increased risk also applies to patients who have abused alcohol, drugs, or narcotics, and patients with personality disorders.
Warnings for specific patient groups
Patients with chronic respiratory failure should be monitored closely due to the risk of respiratory depression.
Patients with mild or moderate liver failure should be treated with caution.
Benzodiazepines should not be given to children without careful evaluation of the justification for their use; the duration of treatment should be as short as possible, and the dose should be individualized for each patient.
The elderly should be given the medicine in a reduced dose.
Before taking any medicine, the patient should consult a doctor or pharmacist.
Pregnancy
The safety of bromazepam use in pregnant women has not been established. Although there are no clinical data on the occurrence of significant congenital malformations in the fetus due to the use of benzodiazepines in the first trimester of pregnancy, some epidemiological studies have shown an increased risk of cleft palate.
Therefore, bromazepam should not be used during pregnancy, unless in exceptional cases and with strict adherence to the dosage regimen.
The patient should contact the doctor about discontinuing treatment if they plan to become pregnant or suspect they are pregnant.
Administration of bromazepam in the third trimester of pregnancy and during childbirth is allowed only in cases of absolute indications, as adverse reactions may occur in newborns, such as hypothermia, decreased muscle tone, which may manifest as problems with sucking (resulting in poor weight gain), and moderate respiratory depression or apnea. Additionally, withdrawal symptoms have been observed in newborns, manifested by excessive excitability, anxiety, and tremors.
In children of mothers who have taken benzodiazepines for a long time in the last period of pregnancy, physical dependence on the medicine and the risk of withdrawal symptoms after birth may occur.
Breastfeeding
Benzodiazepines pass into breast milk, so breastfeeding women should not take Lexotan.
The patient should not drive vehicles or operate machinery, as Lexotan may cause excessive sedation and amnesia, disrupt concentration and muscle function. In case of sleep deprivation, the likelihood of decreased alertness may increase. This effect may be enhanced, especially if the patient has consumed alcohol.
The patient should tell the doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Concomitant use of Lexotan with any medicines that depress the activity of the central nervous system (such as antidepressants, sedatives, narcotic analgesics, neuroleptics, anxiolytics, anticonvulsants, sedatives, antihistamines with a sedative effect, anesthetics) and alcohol may enhance the sedative effect of the medicine and increase its inhibitory effect on the respiratory and circulatory systems.
In the case of the use of narcotic analgesics, a state of euphoria may occur, leading to an increased risk of psychological dependence.
Substances that inhibit the activity of certain liver enzymes may affect benzodiazepines that are metabolized by these enzymes. Concomitant administration of Lexotan with cimetidine, fluvoxamine, or (probably) propranolol may cause its stronger or prolonged effect.
Lexotan contains lactose.If the patient has previously been diagnosed with intolerance to some sugars, they should consult a doctor before taking Lexotan.
This medicine should always be taken according to the doctor's instructions. In case of doubts, the patient should consult a doctor.
Lexotan is available in a dose of 3 mg and 6 mg.
In each case, Lexotan should be taken under the doctor's supervision.
Usually, the recommended dose is:
average doses for outpatients: 1.5 mg to 3 mg, three times a day.
severe cases, especially in hospital treatment: 6 mg to 12 mg, two or three times a day.
The doctor should treat the given dosage as general guidelines and individualize the dose for each patient. Outpatient treatment should be started with small doses, gradually increasing them to the optimal size. Treatment should be as short as possible.
The patient should regularly visit the doctor to assess the need for further administration of the medicine, especially in situations where no symptoms of the disease are observed. The total duration of therapy should not exceed 8 to 12 weeks, including the period of gradual withdrawal of the medicine.
In some cases, therapy may last longer, provided that a specialized assessment of the patient's condition is performed by the doctor.
Older patients and patients with liver function disorders require smaller doses.
If the patient feels that the effect of Lexotan is too strong or too weak, they should consult a doctor.
In case of taking a higher dose of Lexotan than recommended, the patient should immediately consult a doctor.
The doctor will decide on further action.
Common symptoms of benzodiazepine overdose include: drowsiness, coordination disorders, speech disorders, and nystagmus.
Overdose of Lexotan rarely threatens life if the medicine is taken alone. However, it may lead to loss of reflexes, apnea, decreased blood pressure, circulatory and respiratory depression, and coma. Coma, if it occurs, usually lasts several hours but may recur and worsen, especially in older people. Symptoms of respiratory depression are more severe in people with underlying respiratory diseases.
Benzodiazepines enhance the effect of other central nervous system depressants (including alcohol).
The patient should not take a double dose to make up for a missed dose.
In case of physical dependence, after discontinuation of treatment, withdrawal symptoms (withdrawal syndrome) may occur.
These may include: headaches, diarrhea, muscle pain, increased anxiety, tension, anxiety, disorientation, and irritability. In severe cases, the following symptoms may occur: impaired perception of reality (derealization), impaired sense of one's own identity (depersonalization), hypersensitivity to sounds, feeling of numbness and tingling of limbs, hypersensitivity to light, noise, and touch, hallucinations, or seizures.
After withdrawal of the medicine, a rebound anxiety may occur - a transient syndrome in which the symptoms that were the reason for the use of Lexotan recur in an intensified form. Other reactions may also occur, such as mood changes, anxiety, or sleep disorders and anxiety.
Since the risk of withdrawal syndrome and rebound phenomenon is greater in case of sudden discontinuation of treatment, it is recommended to gradually reduce the dose of Lexotan.
In case of any further doubts related to the use of this medicine, the patient should consult a doctor.
Like all medicines, Lexotan can cause side effects, although they may not occur in every patient.
The following side effects have been reported with an unknown frequency (cannot be estimated from the available data):
Dependence:
Long-term use of the medicine (even in therapeutic doses) may lead to the development of physical and psychological dependence on the medicine, and discontinuation of treatment may cause withdrawal symptoms or rebound anxiety (exacerbation of disease symptoms - see "Discontinuation of Lexotan").
There have been reports of benzodiazepine abuse .
If any side effects occur, including any side effects not listed in the leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Reporting side effects can help gather more information on the safety of the medicine.
The medicine should be stored in a place inaccessible and invisible to children.
Do not store above 30°C.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the given month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask the pharmacist what to do with medicines that are no longer needed. This will help protect the environment.
Lexotan is in the form of tablets.
The packaging contains 30 tablets, in blisters, placed in a cardboard box.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
Delpharm Milano S.R.L.
Italy
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in Greece, the country of export: 119950/13-11-2020
Parallel import authorization number: 312/23
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.